Skip to main content
. Author manuscript; available in PMC: 2022 Apr 1.
Published in final edited form as: FEBS J. 2021 May 13;288(19):5629–5649. doi: 10.1111/febs.15858

Figure 8. Comparison of metabolic inhibitor sensitivities in EV- and KRAS-HMECs.

Figure 8.

Ratio of inhibitor-treated to DMSO control growth rates for EGF-titrated EV-HMECs (excluding EGF-free condition) and KRAS-HMECs cultured in 5 ng/ml EGF (+EGF) and 0 ng/ml EGF (−EGF). Inhibitors: a, 10 μM STF-31 (GLUT1 inhibitor) and b, 10 μM phenformin (respiratory complex I inhibitor). The complete set of data are shown on the left, and zoomed perspectives on the KRAS-HMEC points along with regression line through the EV-HMEC points at the three highest growth rates are shown on the right.

Error bars represent mean ± SD for n = 2 or 3 wells. A single experiment was performed for each inhibitor. n.s., not significant, p < 0.025 (Outlier shift model).